Estimación de los costos directos médicos netos de la atención de Cáncer de Mama en el sistema general de seguridad social en salud de Colombia

Vista sencilla de ítem
dc.contributor.advisorHincapié Echeverry, Ana Luciaspa
dc.contributor.advisorDíaz Rojas, Jorge Augustospa
dc.contributor.authorUrrego Novoa, José Ricardospa
dc.contributor.researchgroupFarmacogenética del Cáncerspa
dc.coverage.countryColombiaspa
dc.date.accessioned2024-11-28T12:55:46Z
dc.date.available2024-11-28T12:55:46Z
dc.date.issued2024
dc.descriptionilustraciones, diagramas, tablasspa
dc.description.abstractObjetivo: Estimar los costos directos médicos netos anuales por paciente, en mujeres con diagnóstico de cáncer de mama y obtener un modelo predictor de costos; con base en la información proveniente de una aseguradora perteneciente al Sistema General de Seguridad Social en Salud de Colombia. Método: Las pacientes con cáncer de mama fueron asociadas con controles sin cáncer, mediante un estudio de casos y controles retrospectivo pareado. Los costos se estimaron por fases de atención, entre el 1 de enero de 2010 hasta el 31 de diciembre de 2016, y se estableció un modelo predictor de costos, mediante algoritmos de aprendizaje supervisado. Resultados: Los costos netos promedio anuales de atención por paciente, fueron más altos en las fases de atención inicial (USD 32.223,12) como final (USD 92.700,40) y más bajos en la continua (29.777,02) y antes del diagnóstico respectivamente (USD 13.233,40). Conclusión: La información obtenida, evidenció que los medicamentos, procedimientos de diagnóstico-tratamiento y la cirugía hospitalaria, presentaron el mayor costo estimado en cada una de las fases de atención para cáncer de mama (Texto tomado de la fuente).spa
dc.description.abstractObjective: To estimate the annual net direct medical costs per patient in women diagnosed with breast cancer and to obtain a cost predictor model based on information from an insurance company belonging to the General System of Social Security in Health in Colombia. Method: Patients with breast cancer were matched with non-cancer controls using a retrospective matched case-control study. Costs were estimated by phases of care, between January 1, 2010, through December 31, 2016, and a cost predictor model was established, using supervised learning algorithms. Results: The average annual net costs of care per patient were highest in the initial (USD 32.223,12) and final (USD 92.700,40) phases of care and lowest in the continuous (29,777.02) and pre-diagnosis phases, respectively (USD 13.233,40). Conclusion: The information obtained showed that drugs, diagnostic-treatment procedures and hospital surgery presented the highest estimated cost in each of the phases of breast cancer care.eng
dc.description.degreelevelDoctoradospa
dc.description.degreenameDoctor en Ciencias Farmacéuticasspa
dc.description.methodsEstudio de tipo analítico retrospectivo de casos y controles pareados para la identificación de los costos atribuibles al cáncer de mama a través de fases de atención en una aseguradora de salud del Sistema General de Seguridad Social en Salud en Colombia (SGSSS)spa
dc.format.extentxxii, 215 páginasspa
dc.format.mimetypeapplication/pdfspa
dc.identifier.instnameUniversidad Nacional de Colombiaspa
dc.identifier.reponameRepositorio Institucional Universidad Nacional de Colombiaspa
dc.identifier.repourlhttps://repositorio.unal.edu.co/spa
dc.identifier.urihttps://repositorio.unal.edu.co/handle/unal/87242
dc.language.isospaspa
dc.publisherUniversidad Nacional de Colombiaspa
dc.publisher.branchUniversidad Nacional de Colombia - Sede Bogotáspa
dc.publisher.facultyFacultad de Cienciasspa
dc.publisher.placeBogotá, Colombiaspa
dc.publisher.programBogotá - Ciencias - Doctorado en Ciencias Farmacéuticasspa
dc.relation.referencesMajeed W, Aslam B, Javed I, Khaliq T, Muhammad F, Ali A, et al. MINI-REVIEW Breast Cancer : Major Risk Factors and Recent Developments in Treatment. 2014;15:3353–8.spa
dc.relation.referencesYin W, Wang J, Jiang L, James Kang Y. Cancer and stem cells. Vol. 246, Experimental Biology and Medicine. SAGE Publications Inc.; 2021. p. 1791–801.spa
dc.relation.referencesInstitute for Health Metrics and Evaluation (IHME). Global Burden of Disease 2021: Findings from the GBD 2021 Study. Seattle, WA; 2024spa
dc.relation.referencesTorre LA, Siegel RL, Ward EM, Jemal A. Global Cancer Incidence and Mortality Rates and Trends — An Update. 2016;25(January):16–28.spa
dc.relation.referencesBray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin [Internet]. 2018;68(6):394–424. Available from: http://www.ncbi.nlm.nih.gov/pubmed/30207593spa
dc.relation.referencesBray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;(February):1–35.spa
dc.relation.referencesDe, Fondo Colombiano de Enfermedades de Alto Costo C de AC (CAC). Situación del cáncer en la población adulta atendida en el SGSSS de Colombia 2022. Bogotá D.C.; 2023.spa
dc.relation.referencesYabroff KR, Lund J, Kepka D, Mariotto A. Economic burden of cancer in the United States: estimates, projections, and future research. Cancer Epidemiol Biomarkers Prev. 2011;20(10):2006–14.spa
dc.relation.referencesDrummond M. SM ,Claxto. C ,Stoddar. g. ,Torranc. G. Methods for the Economic Evaluation of Health Care Programmes. Fourth. New York: Oxford University Press; 2015.spa
dc.relation.referencesJo C. Cost-of-illness studies : concepts , scopes , and methods. 2014;327–37.spa
dc.relation.referencesLipscomb J, Yabroff KR, Brown ML, Lawrence W, Barnett PG. Health Care Costing: Data, Methods, Current Applications. Med Care [Internet]. 2009;47(7_Supplement_1):S120–6. Available from: http://journals.lww.com/lww-medicalcare/Fulltext/2009/07001/Health_Care_Costing__Data,_Methods,_Current.1.aspx %5Cnhttp://journals.lww.com/lww-medicalcare/Fulltext/2009/07001/Inventory_of_Data_Sources_for_Estimating_Health.21.aspx %5Cnhttp://journals.lww.spa
dc.relation.referencesGallardo-Solarte K. K, Benavides-Acosta F.P. FP, Rosales-Jiménez R. R. Costos de la enfermedad crónica no transmisible: la realidad colombiana. Ciencias la Salud [Internet]. 2016;14(1):103–14. Available from: http://revistas.urosario.edu.co/index.php/revsalud/article/view/4596spa
dc.relation.referencesBarlow WE. Overview of methods to estimate the medical costs of cancer. Med Care. 2009;July(47(7 Suppl 1)):S33–S36.spa
dc.relation.referencesGamboa Ó, Buitrago LA, Lozano T, Dieleman S, Gamboa C, Guzmán ÉL, et al. Costos directos de la atención del cáncer de mama en Colombia. Rev Colomb Cancerol [Internet]. 2016;20(2):52–60. Available from: http://linkinghub.elsevier.com/retrieve/pii/S0123901516300014spa
dc.relation.referencesArredondo A, Damián T. Costos economicos en la produccion de servicios de salud: Del costo de los insumos al costo de manejo de caso. Salud Publica Mex. 1997;39(2):117–24spa
dc.relation.referencesCerda L J. Glosario de términos utilizados en evaluación económica de la salud. Rev Med Chil [Internet]. 2010;138(Supl 2):76–8. Available from: http://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0034-98872010001000003&lng=es&nrm=iso&tlng=esspa
dc.relation.referencesRipari Nadia MNEM. Costos de enfermedades: una revisión crítica de las metodologías de estimación. Lect Econ [Internet]. 2012;(77):253–82. Available from: http://www.scielo.org.co/scielo.php?script=sci_arttext&pid=S0120-25962012000200008&lang=ptspa
dc.relation.referencesInstituto de Evaluación Tecnológica en Salud - IETS. Manual metodológico para la elaboración de análisis de impacto presupuestal de tecnologías en salud en Colombia. Bogota D.C.; 2023.spa
dc.relation.referencesMinisterio de salud y protección [Internet]. Manual Tarifario SOAT 2024 [Internet]. 2024. p. 4–6. Available from: https://consultorsalud.com/manual-tarifario-soat-2024-version-pdf/spa
dc.relation.referencesAminuddin F, Bahari MS, Zainuddin NA, Hanafiah ANM, Hassan NZAM. The Direct and Indirect Costs of Cancer among the Lower-Income Group: Estimates from a Pilot and Feasibility Study. Asian Pacific J Cancer Prev. 2023;24(2):489–96.spa
dc.relation.referencesXia Y, Chen Y, Chen J, Gan Y, Su C, Zhang H, et al. Measuring direct non-medical burden among patients with advanced non-small cell lung cancer in China: is there a difference in health status? Front Public Heal. 2023;11spa
dc.relation.referencesMohammadpour S, Soleimanpour S, Javan-Noughabi J, Gallehzan NA, Aboutorabi A, Jahangiri R, et al. A systemmatic literature review on indirect costs of women with breast cancer. Vol. 20, Cost Effectiveness and Resource Allocation. BioMed Central Ltd; 2022.spa
dc.relation.referencesBarchuk A, Bespalov A, Huhtala H, Chimed T, Belyaev A, Moore M, et al. Productivity losses associated with premature mortality due to cancer in Russia: A population-wide study covering 2001–2030. Scand J Public Health. 2019 Jul 1;47(5):482–91.spa
dc.relation.referencesBugge C, Sæther EM, Brustugun OT, Kristiansen IS. Societal cost of cancer in Norway –Results of taking a broader cost perspective. Health Policy (New York). 2021 Aug 1;125(8):1100–7.spa
dc.relation.referencesPalacios A, Rojas-Roque C, González L, Bardach A, Ciapponi A, Peckaitis C, et al. Direct Medical Costs, Productivity Loss Costs and Out-Of-Pocket Expenditures in Women with Breast Cancer in Latin America and the Caribbean: A Systematic Review. Vol. 39, PharmacoEconomics. Adis; 2021. p. 485–502.spa
dc.relation.referencesGianino MM, Lenzi J, Bonaudo M, Fantini MP, Siliquini R. Organized screening programmes for breast and cervical cancer in 17 EU countries : trajectories of attendance rates. 2018;1–13.spa
dc.relation.referencesGuy GP, Yabroff KR, Ekwueme DU, Rim SH, Li R, Richardson LC. Economic burden of chronic conditions among survivors of cancer in the United States. J Clin Oncol. 2017;35(18):2053–61.spa
dc.relation.referencesVazin A, Karimzadeh I, Karamikhah R, Oveisi Z, Mohseni S, Keykhaee M, et al. Clinical and economical impacts of guideline implementation by the pharmaceutical care unit for high cost medications in a referral teaching hospital. BMC Health Serv Res. 2018;18(1):1–10.spa
dc.relation.referencesDiaz JA, Urrego-Novoa JR, Moreno JA, Huerfano C, Prieto VA. Analisis de Costo-Efectividad de Anidulafungina en el Tratamiento de la Candidiasis Invasiva en Colombia. Value Heal. 2015;18(7):A870.spa
dc.relation.referencesŠpacírová Z, Epstein D, García-Mochón L, Rovira J, Olry de Labry Lima A, Espín J. A general framework for classifying costing methods for economic evaluation of health care. Eur J Heal Econ. 2020 Jun 1;21(4):529–42.spa
dc.relation.referencesMihalopoulos C, Le LKD, Chatterton M Lou, Bucholc J, Holt-Lunstad J, Lim MH, et al. The economic costs of loneliness: a review of cost-of-illness and economic evaluation studies. Vol. 55, Social Psychiatry and Psychiatric Epidemiology. Springer; 2020. p. 823–36.spa
dc.relation.referencesWu J, Liu H, Hu T, Long M, Zhou X, Wang S. The natural history of breast cancer: a chronological analysis of breast cancer progression using data from the SEER database. Ann Transl Med. 2022 Mar;10(6):365–365.spa
dc.relation.referencesFranklin M, Pollard D, Sah J, Rayner A, Sun Y, Dube F, et al. Direct and Indirect Costs of Breast Cancer and Associated Implications: A Systematic Review. Vol. 41, Advances in Therapy. Adis; 2024. p. 2700–22.spa
dc.relation.referencesIbarrondo O, Lizeaga G, Martínez-Llorente JM, Larrañaga I, Soto-Gordoa M, Álvarez-López I. Health care costs of breast, prostate, colorectal and lung cancer care by clinical stage and cost component. Gac Sanit. 2022 May 1;36(3):246–52.spa
dc.relation.referencesOmer AAA, Bin Dayel SA, Hummedi ASA, Almuhaimed NIA. The epidemiological and clinicopathological features of breast cancer in Riyadh, Saudi Arabia. Saudi Med J. 2024;45(3):288–94spa
dc.relation.referencesRivero Cuadrado A. Guía Pedagógica para la Implementación de los sistemas de clasificación de pacientes (Grd) en instituciones prestadoras de servicios de salud (Ips). Bogotá D.C.; 2012.spa
dc.relation.referencesGorbanev I, Cortés Martínez AE, Agudelo Londoño S, Yepes Lujan FJ. Grupos relacionados por el diagnóstico: experiencia en tres hospitales de alta complejidad en Colombia. Univ Médica [Internet]. 2016;57(2):171–81. Available from: http://revistas.javeriana.edu.co/index.php/vnimedica/article/view/17031spa
dc.relation.referencesDuque MI, Fernando Gómez R-L, Albeiro M-J, Agudelo O, Isabel M, Roldán D, et al. Análisis De Los Sistemas De Costos Utilizados En Las Entidades Del Sector Salud En Colombia Y Su Utilidad Para La Toma De Decisiones. Rev del Inst Int Costos. 2009;525.spa
dc.relation.referencesWilkinson AN, Seely JM, Rushton M, Williams P, Cordeiro E, Allard-Coutu A, et al. Capturing the True Cost of Breast Cancer Treatment: Molecular Subtype and Stage-Specific per-Case Activity-Based Costing. Curr Oncol. 2023 Sep 1;30(9):7860–73.spa
dc.relation.referencesInstitute for Quality and Efficiency in Health Care (IQWiG). General Methods - Version 6.1 [Internet]. Germany; 2022 Jan [cited 2024 Oct 12]. Available from: https://www.ispor.org/heor-resources/more-heor-resources/pharmacoeconomic-guidelines/pe-guideline-detail/germanyspa
dc.relation.referencesChicaiza Becerra L, García Molina M, Oviedo S, Urrego J, Rincón C RA y GP. Costo efectividad del suplemento de calcio para reducir la mortalidad materna asociada a la preeclampsia. Bogotá D.C.; 2015. (Documentos FCE-CID). Report No.: 34spa
dc.relation.referencesHaji-Sheikhi F, Fragala MS, Bare LA, Rowland CM, Goldberg SE. Prediction of Future Medical Costs by Modifiable Measures of Health. Clin Outcomes Res. 2023;15:525–34.spa
dc.relation.referencesKim DD, Silver MC, Kunst N, Cohen JT, Ollendorf DA, Neumann PJ. Perspective and Costing in Cost-Effectiveness Analysis, 1974–2018. Pharmacoeconomics. 2020 Oct 1;38(10):1135–45.spa
dc.relation.referencesMarques ICP, Alves MC. Hospital Costing Methods: Four Decades of Literature Review. J Risk Financ Manag. 2023 Oct 1;16(10).spa
dc.relation.referencesMinisterio de Salud y Protección Social; Instituto de Evaluación Tecnológica en Salud; Instituto Nacional de Cancerología. Guía De Práctica Clínica para la detección temprana, tratamiento integral, seguimiento y rahabilitación del cáncer de mama. Guía para profesionales de la salud [Internet]. Bogotá D.C.; 2017. Available from: http://imss.gob.mx/profesionales-salud/gpcspa
dc.relation.referencesFaria R MA. Documentos técnicos de apoyo a la construcción del caso de referencia colombiano para la evaluación económica en salud. Bogotá DC: Instituto de Evaluación Tecnológica - IETS [Internet]. Bogotá D.C.; 2014. Available from: http://www.iets.org.co/Manuales/Manuales/Documentos-tecnicos-espanol.pdfspa
dc.relation.referencesXu X, Nardini HKG, Ruger JP. Micro-costing studies in the health and medical literature: Protocol for a systematic review. Syst Rev. 2014;3(1):1–7spa
dc.relation.referencesTan SS, Bouwmans CAM, Rutten FFH, Hakkaart-Van Roijen L. Update of the dutch manual for costing in economic evaluations. Int J Technol Assess Health Care. 2012;28(2):152–8.spa
dc.relation.referencesBergmo TS. How to measure costs and benefits of ehealth interventions: An overview of methods and frameworks. J Med Internet Res. 2015;17(11).spa
dc.relation.referencesGuerrero-c R, Parody G, Fe S, Osorio DI. Guía Metodológica Realización de Evaluaciones Económicas en el marco de Guías de Práctica Clínica - Versión final completa. 2014spa
dc.relation.referencesParada-vargas LA, Taborda-restrepo A. Modelos de evaluación económica: sua aplicación en las decisiones sanitaria. Rev Colomb Psiiquiat. 2011;40(2):352–62spa
dc.relation.referencesSamuelson P NW. Economía. 18th ed. Madrid, España: Mc Graw Hill/Interamericana de España; 2006. 122–38 p.spa
dc.relation.referencesRipari NEMMN. Costos de enfermedades : clasificación y perspectivas de análisis. Rev Cienc Salud. 2017;15(1):49–58.spa
dc.relation.referencesHutton G, Baltussen R. Cost valuation in resource-poor settings. Health Policy Plan. 2005;20(4):252–9.spa
dc.relation.referencesMargier J, Baffert S, Le Corroller-Soriano AG, Baffert S, Bertaux AC, Bonastre J, et al. Standard or specific unit costs: Which criteria for choosing an economic evaluation of health strategies in multicentric studies? Rev Epidemiol Sante Publique. 2018;66:S93–9.spa
dc.relation.referencesLipscomb J, Barnett PG, Brown ML, Lawrence WF, Yabroff KR, Lund JL, et al. Health Care Costing: Data, Methods, Current Applications. Med Care [Internet]. 2009;47(7_Supplement_1):S120–S126. Available from: http://journals.lww.com/lww-medicalcare/Fulltext/2009/07001/Health_Care_Costing__Data,_Methods,_Current.1.aspxspa
dc.relation.referencesWijeysundera HC, Wang X, Tomlinson G, Ko DT, Krahn MD. Techniques for estimating health care costs with censored data: An overview for the health services researcher. Vol. 4, ClinicoEconomics and Outcomes Research. Dove Medical Press Ltd; 2012. p. 145–55spa
dc.relation.referencesBrown, ML; Riley, GF; Schussler, N; Etzioni R. Estimating Health Care Costs Related to Cancer Treatment From SEER-Medicare Data. Med Care. 2002;40(8, Supplement):104–17spa
dc.relation.referencesYabroff KR, Warren JL, Schrag D, Mariotto A, Meekins A, Topor M, et al. Comparison of Approaches for Estimating Incidence Costs of Care for Colorectal Cancer Patients. Med Care [Internet]. 2009;47(Supplement):S56–63. Available from: http://insights.ovid.com/crossref?an=00005650-200907001-00010spa
dc.relation.referencesYabroff KR, Lamont EB, Mariotto A, Warren JL, Topor M, Meekins A, et al. Cost of care for elderly cancer patients in the United States. J Natl Cancer Inst. 2008;100(9):630–41.spa
dc.relation.referencesMariotto AB, Enewold L, Zhao J, Zeruto CA, Robin Yabroff K. Medical care costs associated with cancer survivorship in the United States. Cancer Epidemiol Biomarkers Prev. 2020;29(7):1304–12.spa
dc.relation.referencesNolan E, Lindeman GJ, Visvader JE. Deciphering breast cancer: from biology to the clinic. Vol. 186, Cell. Elsevier B.V.; 2023. p. 1708–28.spa
dc.relation.referencesAkram M, Iqbal M, Daniyal M, Khan AU. Awareness and current knowledge of breast cancer. Biol Res. 2017;50(1):33.spa
dc.relation.referencesSinn HP, Kreipe H. A brief overview of the WHO classification of breast tumors, 4th edition, focusing on issues and updates from the 3rd edition. Breast Care. 2013;8(2):149–54.spa
dc.relation.referencesHayes DF, Lippman ME. Breast Cancer. In: Loscalzo J, Fauci A, Kasper D, Hauser S, Longo D, Jameson JL, editors. Harrison’s Principles of Internal Medicine, 21e [Internet]. New York, NY: McGraw-Hill Education; 2022. Available from: accessmedicine.mhmedical.com/content.aspx?aid=1198035878spa
dc.relation.referencesSilva SN, Gomes BC, André S, Félix A, Rodrigues AS, Rueff J. Male and female breast cancer: the two faces of the same genetic susceptibility coin. Breast Cancer Res Treat. 2021 Jul 1;188(1):295–305.spa
dc.relation.referencesFondo Colombiano de Enfermedades de Alto Costo C de AC (CAC). Situación del cáncer en la población adulta atendida en el SGSSS de Colombia 2023. Bogotá D.C.; 2024 Sep.spa
dc.relation.referencesParsa Y, Mirmalek SA, Kani FE, Aidun A, Salimi-tabatabaee SA, Yadollah-damavandi S, et al. A Review of the Clinical Implications of Breast Cancer Biology. Electron Physician. 2016;8(5):2416–24.spa
dc.relation.referencesBriceño-Balcázar I, Gómez-Gutiérrez A, Díaz-Dussán NA, Noguera-Santamaría MC, Díaz-Rincón D, Casas-Gómez MC. Mutational spectrum in breast cancer associated BRCA1 and BRCA2 genes in Colombia / Espectro de mutaciones en los genes BRCA1 y BRCA2 asociados a cáncer de mama en Colombia. Colomb Médica VO - 48 [Internet]. 2017;48(2):58. Available from: http://www.bvsspa.es/papi/ezproxy.php?url=http://search.ebscohost.com/login.aspx?direct=true&db=edssci&AN=edssci.S1657.95342017000200058&amp%0Alang=es&site=eds-live&scope=sitespa
dc.relation.referencesCouch, F; DeShano, M; Blackwood, MA; Calzone, K; Stopfer, J; Campeau, L; Ganguly, A; Rebbeck, T; Weber B. BRCA1 Mutations in Women Attending Clinics that Evaluate the Risk of Breast Cancer. N Engl J Med. 1999;336(20):1409–15.spa
dc.relation.referencesChafidz A, Kaavessina M, Al-Zahrani S, Al-Otaibi MN. Cancer Staging Manual Seventh Edition. 7th ed. Springer, editor. American Joint Comittee on Cancer. Chicago; 2016. 345–376 p.spa
dc.relation.referencesLü Y, Cai MH, Cheng J, Zou K, Xiang Q, Wu JY, et al. A multi-center nested case-control study on hospitalization costs and length of stay due to healthcare-associated infection. Antimicrob Resist Infect Control. 2018;7(1):1–10.spa
dc.relation.referencesKeats MR, Cui Y, DeClercq V, Grandy SA, Sweeney E, Dummer TJB. Burden of multimorbidity and polypharmacy among cancer survivors: a population-based nested case–control study. Support Care Cancer. 2021;29(2):713–23spa
dc.relation.referencesOrganización Panamericana de la Salud. CIE-10 Clasificación Estadística Internacional de Enfermedades y Problemas Relacionados con la Salud Volumen 1 Introducción Centros Colaboradores de la OMS para la Clasificación de Enfermedades Informe de la Conferencia Internacional para la Décima Revisi. 2003;(554):1–1158. Available from: http://iris.paho.org/xmlui/bitstream/handle/123456789/6282/Volume1.pdfspa
dc.relation.referencesOrganización Panamericana de la Salud. Clasificación estadística internacional de enfermedades y problemas relacionados con la salud 10a revisión. Washington D.C., E.U.A.; 1995.spa
dc.relation.referencesRuíz F, Escobar GM, Milena Cuellar Segura C, Teresa Buitrago Grupo ME, María Henríquez Grupo GM, Stella Ríos Grupo LM, et al. Plan Decenal Salud Pública 2022-2031. Bogotá D.C.; 2022 Apr.spa
dc.relation.referencesMaría A, Ligia I-B, Melo-Becerra A, Estefanía D, María P-A, Ramírez-Giraldo T. Evolución y carga financiera de las Enfermedades Crónicas no Transmisibles en Colombia: 2010-2021. 2023.spa
dc.relation.referencesColombia. Ministerio de Salud y Protección Social. Oficina de Tecnología de la Información y la Comunicaciones. Lineamiento Técnico para el Registro y envío de los datos del Registro Individual de Prestaciones de Salud – RIPS, desde las Instituciones Prestadoras de Servicios de Salud. Bogotá D.C.; 2019.spa
dc.relation.referencesGuillen A, Araiza L a, Cerna E, Valenzuela J, Uanl JL, Nicolás S, et al. Métodos No Paramétricos de Uso Común. DAENA Int J Good Conscienc. 2012;7(1):132–55.spa
dc.relation.referencesBürkner PC, Doebler P, Holling H. Optimal design of the Wilcoxon–Mann–Whitney-test. Biometrical J. 2017;59(1):25–40.spa
dc.relation.referencesNeus Canal Díaz. Distribuciones de probabilidad. El teorema central del límite. Rev Seden. 2006;107–20.spa
dc.relation.referencesHajian-Tilaki K. Sample size estimation in epidemiologic studies. Casp J Intern Med. 2011;2(4):289–98.spa
dc.relation.referencesKing G, Nielsen R, Coberley C, Pope JE. Comparative Effectiveness of Matching Methods for Causal Inference. Unpubl Manuscr. 2011;15:1–26.spa
dc.relation.referencesRosenbaum PR, Rubin DB. The Central Role of the Propensity Score in Observational Studies for Causal Effects Published by : Biometrika Trust Stable URL : http://www.jstor.org/stable/2335942. Biometrika. 1983;70(1):41–55.spa
dc.relation.referencesFullerton B, Pöhlmann B, Krohn R, Adams JL, Gerlach FM, Erler A. The Comparison of Matching Methods Using Different Measures of Balance: Benefits and Risks Exemplified within a Study to Evaluate the Effects of German Disease Management Programs on Long-Term Outcomes of Patients with Type 2 Diabetes. Health Serv Res. 2016;51(5):1960–80.spa
dc.relation.referencesIacus SM, King G, Porro G. Causal inference without balance checking: Coarsened exact matching. Polit Anal. 2012;20(1):1–24spa
dc.relation.referencesIacus SM, King G, Porro G. cem: Software for Coarsened Exact Matching. J Stat Softw [Internet]. 2009;30(9):1–27. Available from: http://www.jstatsoft.org/spa
dc.relation.referencesIacus SM, King G, Porro G. Multivariate matching methods that are monotonic imbalance bounding. J Am Stat Assoc. 2011;106(493):345–61.spa
dc.relation.referencesSun L, Legood R, Dos-Santos-Silva I, Gaiha SM, Sadique Z. Global treatment costs of breast cancer by stage: A systematic review. PLoS One. 2018;13(11):1–14.spa
dc.relation.referencesBelger M, Haro JM, Reed C, Happich M, Kahle-Wrobleski K, Argimon JM, et al. How to deal with missing longitudinal data in cost of illness analysis in Alzheimer’s disease - Suggestions from the GERAS observational study. BMC Med Res Methodol [Internet]. 2016;16(1). Available from: http://dx.doi.org/10.1186/s12874-016-0188-1spa
dc.relation.referencesAzur MJ, Stuart EA, Frangakis C, Leaf PJ. MICE - What is it, and how does it work. Int J Methods Psychiatr. 2012;20(1):40–9.spa
dc.relation.referencesGraham JW. Missing Data Analysis: Making It Work in the Real World. Annu Rev Psychol. 2008;60(1):549–76.spa
dc.relation.referencesMedina F, Galván M. Imputación de datos: teoría y práctica [Internet]. Vol. 4, Estudios estadísticos y prospectivos. 2007. 84 p. Available from: http://www.cepal.org/publicaciones/xml/8/14038/lc2024e.pdfspa
dc.relation.referencesSterne JAC, White IR, Carlin JB, Spratt M, Royston P, Kenward MG, et al. Multiple imputation for missing data in epidemiological and clinical research: Potential and pitfalls. BMJ. 2009;339(7713):157–60spa
dc.relation.referencesHiggins JPT, Green S. Manual Cochrane de revisiones sistemáticas de intervenciones. Cochrane [Internet]. 2011;(March):1–639. Available from: http://www.cochrane.es/?q=es/node/269spa
dc.relation.referencesMihaylova B.; Briggs A.; O´Hagan A. and Thompson S. Review of Statistical Methods For Analysing Healthcare Recources And Costs. 2008;1131(2007):1127–31.spa
dc.relation.referencesMorid MA, Kawamoto K, Ault T, Dorius J, Abdelrahman S. Supervised Learning Methods for Predicting Healthcare Costs: Systematic Literature Review and Empirical Evaluation. AMIA . Annu Symp proceedings AMIA Symp. 2017;2017:1312–21spa
dc.relation.referencesBotchkarev A. Evaluating Performance of Regression Machine Learning Models Using Multiple Error Metrics in Azure Machine Learning Studio. SSRN Electron J. 2018;1–16.spa
dc.relation.referencesGuarín A, Ramírez A, Torres F. Modelos Multinomiales : Un análisis de sus propiedades. Rev Ing Medellín. 2012;11(20):87–103.spa
dc.relation.referencesHossain MZ. A Review On Some Alternative Specifications Of The Logit Model. J Bus Econ Res. 2011;7(12):15–24.spa
dc.relation.referencesFernández PV. SMFR. Regresion Logística Multinomial. CuadSocCienFor. 2004;18:323–7.spa
dc.relation.referencesYang C, Delcher C, Shenkman E, Ranka S. Machine learning approaches for predicting high cost high need patient expenditures in health care 08 Information and Computing Sciences 0801 Artificial Intelligence and Image Processing. Biomed Eng Online [Internet]. 2018;17(S1):1–20. Available from: https://doi.org/10.1186/s12938-018-0568-3spa
dc.relation.referencesRutten-van Mölken MP, van Doorslaer EK, van Vliet RC. Statistical analysis of cost outcomes in a randomized controlled clinical trial. Health Econ. 1994;3(5):333–45.spa
dc.relation.referencesGregori D, Petrinco M, Bo S, Desideri A, Merletti F, Pagano E. Regression models for analyzing costs and their determinants in health care: An introductory review. Int J Qual Heal Care. 2011;23(3):331–41.spa
dc.relation.referencesManning WG, Mullahy J. Estimating log models: To transform or not to transform? J Health Econ. 2001;20(4):461–94spa
dc.relation.referencesPowers CA, Meyer CM, Roebuck MC, Vaziri B. Predictive modeling of total healthcare costs using pharmacy claims data: A comparison of alternative econometric cost modeling techniques. Med Care. 2005;43(11):1065–72.spa
dc.relation.referencesGriswold M, Parmigiani G PA and LJ. Analyzing Health Care Costs: A Comparison of Sattistical Methods Motivated by Medicare Colorectal Cancer Charges. Biostatistics. 2004;1(1):1–23.spa
dc.relation.referencesCenter IK. Análisis vecino más cercano [Internet]. 1. Análisis vecino más cercano [Internet]. [cited 2019 Nov 9]. Available from: https://www.ibm.com/support/knowledgecenter/es/SSLVMB_sub/statistics_mainhelp_ddita/spss/base/idh_idd_knn_variables.html. 2019 [cited 2019 Nov 9]. Available from: https://www.ibm.com/support/knowledgecenter/es/SSLVMB_sub/statistics_mainhelp_ddita/spss/base/idh_idd_knn_variables.htmlspa
dc.relation.referencesKumar RR, Viswanath P, Bindu CS. Nearest Neighbor Classifiers : A Review. 2017;13(2):303–11.spa
dc.relation.referencesKataria A, Singh MD. International Journal of Emerging Technology and Advanced Engineering A Review of Data Classification Using K-Nearest Neighbour Algorithm. Certif J [Internet]. 2008;9001(6):354–60. Available from: www.ijetae.comspa
dc.relation.referencesSushmita S, Newman S, Marquardt J, Ram P, Prasad V, De Cock M, et al. Population cost prediction on public healthcare datasets. ACM Int Conf Proceeding Ser. 2015;2015-May:87–94.spa
dc.relation.referencesRucci P, Avaldi VM, Travaglini C, Ugolini C, Berti E, Moro ML, et al. Medical Costs of Patients with Type 2 Diabetes in a Single Payer System: A Classification and Regression Tree Analysis. PharmacoEconomics - Open [Internet]. 2019;(0123456789). Available from: https://doi.org/10.1007/s41669-019-0166-8spa
dc.relation.referencesKang JO, Chung S-H, Suh Y-M. Prediction of Hospital Charges for the Cancer Patients with Data Mining Techniques. J Korean Soc Med Informatics. 2009;15(1):13spa
dc.relation.referencesShahid N, Rappon T, Berta W. Applications of artificial neural networks in health care organizational decision-making: A scoping review. PLoS One. 2019;14(2):1–22.spa
dc.relation.referencesMinisterio de Salud. Resolución 3374 de 2000. 2000;2000(44). 116. Ministerio de Salud y Protección Social. Guía Metodológica Nacional para la Caracterización de Fuentes de Información para la Salud en Colombia. 2014;58. Available from: https://www.minsalud.gov.co/sites/rid/Lists/BibliotecaDigital/RIDE/VS/ED/GCFI/guia definitiva 19062014.pdfspa
dc.relation.referencesBarlow WE. Overview of Methods to Estimate the Medical Costs of Cancer. Med Care. 2009;July(47(7 Suppl 1)):S33–S36.spa
dc.relation.referencesOliveira C, Pataky R, Bremner K, Rangrej J, Chan KKW, Cheung WY, et al. Phase-specific and lifetime costs of cancer care in Ontario, Canada. BMC Cancer [Internet]. 2016;16(1):1–12. Available from: http://dx.doi.org/10.1186/s12885-016-2835-7spa
dc.relation.referencesP MZS. The main methodological issues in costing health care services. A literature review. 2005. Report No.: CHE Research Paper 7.spa
dc.relation.referencesInstituto de Evaluación Tecnológica en Salud. Manual para la elaboración de evaluaciones económicas en salud. Bogotá D.C.; 2014.spa
dc.relation.referencesNacionales D de I y A. ISO 4217 Códigos de Monedas. Bogotá D.C.; 2015.spa
dc.relation.referencesKwak SG, Kim JH. Central limit theorem: The cornerstone of modern statistics. Korean J Anesthesiol. 2017;70(2):144–56.spa
dc.relation.referencesKim J, Bang H. Three common misuses of P values. Dent Hypotheses. 2016;7(3):73–80.spa
dc.relation.referencesJason B. Statistical Methods for Maching Learning. Machine Le. 2019. 64–70spa
dc.relation.referencesVapnik V. Statistical Learning Theory. Wiley, editor. New York; 1998. 19–55 p.spa
dc.relation.referencesO. Jiménez, N. Dussan, L. Sanabria JR. Indicadores de oportunidad reportados por las Entidades Administradoras de Planes de Beneficios a la Superintendencia Nacional de Salud (SNS) durante la vigencia 2012-2013. Seguimiento al cumplimiento del Decreto 019 de 2012. Monit Estratégico. 2014;1(5):55–69.spa
dc.relation.referencesEkwueme DU, Allaire BT, Guy GP, Arnold S, Trogdon JG. Treatment Costs of Breast Cancer among Younger Women Aged 19-44 Years Enr1. Ekwueme DU, Allaire BT, Guy GP, Arnold S, Trogdon JG. Treatment Costs of Breast Cancer among Younger Women Aged 19-44 Years Enrolled in Medicaid. Am J Prev Med [Internet]. 2016;50. Am J Prev Med [Internet]. 2016;50(2):278–85. Available from: http://dx.doi.org/10.1016/j.amepre.2015.10.017spa
dc.relation.referencesCuenta de Alto Costo. Fondo Colombiano de Enfermedades de Alto Costo. Situación del cáncer en la población adulta atendida en el SGSSS de Colombia 2017. Vol. 91, Situación Del Cancer En Colombia 2017. Bogotá D.C.; 2017.spa
dc.relation.referencesDíaz Carolina García Magdalena León Felipe Ruiz Francisca Torres Docentes I, Lizama P, Boccardo G. Guía de Asociación entre variables (Pearson y Spearman en SPSS). Santiago de Chile; 2014.spa
dc.relation.referencesLahiri B, Agarwal N. Predicting Healthcare Expenditure Increase for an Individual from Medicare Data. 2014;8.spa
dc.relation.referencesKotu V, Deshpande B. Model Evaluation. In: Data Science. 2019. p. 263–79.spa
dc.relation.referencesMartínez Rodríguez M. Errores frecuentes en la interpretación del coeficiente de determinación lineal. Anu jurídico y económico Escur. 2005;(38):315–31.spa
dc.relation.referencesBewick V, Cheek L, Ball J. Statistics review 7: Correlation and regression. Crit Care. 2003;7(6):451–9spa
dc.relation.referencesKvylseth TO. Cautionary note about r2. Am Stat. 1985;39(4):279–85.spa
dc.relation.referencesChai T, Draxler RR. Root mean square error (RMSE) or mean absolute error (MAE)? -Arguments against avoiding RMSE in the literature. Geosci Model Dev. 2014;7(3):1247–50spa
dc.relation.referencesPiñeros M, Abriata MG, Les M, Bray F. Cancer registration for cancer control in Latin America: a status and progress report. Rev Panam Salud Publica [Internet]. 2017;41. Available from: https://cdn.digital.gob.cl/filer_public/d3/0a/d30a1f5e-53d9-4a31-a4fe-e90d8d9a2348/documento_plan_nacional_de_cancer.pdfspa
dc.relation.referencesRummel S, Hueman MT, Costantino N, Shriver CD, Ellsworth RE. Tumour location within the breast: Does tumour site have prognostic ability? Ecancermedicalscience. 2015;9:1–10.spa
dc.relation.referencesSiotos C, McColl M, Psoter K, Gilmore RC, Sebai ME, Broderick KP, et al. Tumor Site and Breast Cancer Prognosis. Clin Breast Cancer [Internet]. 2018;18(5):e1045–52. Available from: https://doi.org/10.1016/j.clbc.2018.05.007spa
dc.relation.referencesFondo Colombiano de Enfermedades de Alto Costo (CAC). La Hipertensión Arterial y la Diabetes Mellitus. Bogotá D.C.; 2023.spa
dc.relation.referencesVerdial FC, Etzioni R, Duggan C, Anderson BO. Demographic changes in breast cancer incidence, stage at diagnosis and age associated with population-based mammographic screening. J Surg Oncol. 2017;115(5):517–22.spa
dc.relation.referencesHaque R, Xu X, Shi J, Kwan ML CR. Breast Cancer Outcomes in a Racially and Ethnically Diverse Cohort of Insured Women. Ethn Dis. 2018;28(4):565–74.spa
dc.relation.referencesMinisterio de Salud y Protección Social-Colciencias. Guia de práctica clínica (GPC) para la detección temprana, tratamiento integral, seguimiento y rehabilitación del cáncer de mama. Bogotá D.C.; 2013 Apr.spa
dc.relation.referencesMinisterio de salud y Proteccion social, Colciencias. Guía de práctica clínica Hipertensión arterial primaria (hta) 2013-Guía No. 18 [Internet]. 2013. 371 p. Available from: https://www.minsalud.gov.co/sites/rid/Lists/BibliotecaDigital/RIDE/INEC/IETS/GPC_Completa_HTA.pdfspa
dc.relation.referencesRepública de Colombia M de S y P social. Guía de Práctica Clínica (GPC) para el diagnóstico, tratamiento y seguimiento de la diabetes mellitus tipo 2 en la población mayor de 18 años. 2015. 606 p.spa
dc.relation.referencesMedina Orjuela A, Rosero Olarte Ó, Nel Rueda Plata P, Sánchez Escobar F, Chalem Choueka M, González Reyes MÁ, et al. II Consenso Colombiano para el Manejo de la Osteoporosis Posmenopáusica. Rev Colomb Reumatol. 2018;25(3):184–210.spa
dc.relation.referencesComisión de Regulación en Salud (CRES). Acuerdo 029 de 2011. Com Regul en Salud [Internet]. 2011;1(03742). Available from: https://www.minsalud.gov.co/salud/pos/mi-plan/Normatividad y estudios de mi plan/Acuerdo 029 pos 2012.pdfspa
dc.relation.referencesPardo C, de Vries E. Supervivencia global de pacientes con cáncer en el Instituto Nacional de Cancerología (INC). Rev Colomb Cancerol. 2017;21(1):12–8.spa
dc.relation.referencesAllemani C, Weir HK, Carreira H, Harewood R, Spika D, Bannon F, et al. Global surveillance of cancer survival 1995–2009: analysis of individual data for 25 676 887 patients from 279 population based registries in 67 countries (CONCORD-2). Lancet. 2015;385(9972):977–1010.spa
dc.relation.referencesGreenland S, Senn SJ, Rothman KJ, Carlin JB, Poole C, Goodman SN, et al. Statistical tests, P values, confidence intervals, and power: a guide to misinterpretations. Eur J Epidemiol. 2016;31(4):337–50.spa
dc.relation.referencesYabroff KR, Lund J, Kepka D, Mariotto A. Economic Burden of Cancer in the United States : Estimates , Projections , and Future Research. Cancer Epidemiol Biomarkers Prev. 2011;20 (10) Oc(October):2006–15.spa
dc.relation.referencesYabroff KR, Lund J, Kepka D, Mariotto A. Economic burden of cancer in the United States : estimates , projections , and future research. Cancer Epidemiol Biomarkers Prev. 2011;20 (10) Oc:2006–15spa
dc.relation.referencesMcLaughlin SA. Surgical Management of the Breast. Breast Conservation Therapy and Mastectomy. Surg Clin North Am [Internet]. 2013;93(2):411–28. Available from: http://dx.doi.org/10.1016/j.suc.2012.12.006spa
dc.relation.referencesHarbeck N, Gnant M. Breast cancer. Lancet [Internet]. 2017;389(10074):1134–50. Available from: http://dx.doi.org/10.1016/S0140-6736(16)31891-8spa
dc.relation.referencesQuiros Enríquez M, Fernández Ruíz DR, Cuevas Pérez OL, Milan vasquez PM, Barrios Romero B, Martínez Barroso T. Revista Electrónica de las Ciencias Médicas en Cienfuegos ISSN:1727-897X Medisur 2012; 10(6). Rev Electrónica las Ciencias Médicas en Cienfuegos. 2012;10(6):495–500.spa
dc.relation.referencesTan GH, Bhoo-Pathy N, Taib NA, See MH, Jamaris S, Yip CH. The will rogers phenomenon in the staging of breast cancer - Does it matter? Cancer Epidemiol [Internet]. 2015;39(1):115–7. Available from: http://dx.doi.org/10.1016/j.canep.2014.11.005spa
dc.relation.referencesOssa CA, Gómez LR, Ascuntar J, García HI. Supervivencia global y libre de enfermedad según subtipo molecular. RevMédica Sánitas [Internet]. 2015;18(3):122–32. Available from: https://bit.ly/31DSRJMspa
dc.relation.referencesVelasco Capellas M, Martínez Peralta S, CerdÀ Serdá P, Estival González A, Fernández Bruno M, Lianes Barragan P. Quimioterapia neoadyuvante en el cáncer de mama localmente avanzado. Rev Senol y Patol Mamar. 2012;25(1):14–21.spa
dc.relation.referencesMurugappan K, Saboo A, Kuo L, Ung O. Paradigm shift in the local treatment of breast cancer: Mastectomy to breast conservation surgery. Gland Surg. 2018;7(6):506–19.spa
dc.relation.referencesYabroff KR, Warren JL, Brown ML. Costs of cancer care in the USA: a descriptive review. Nat Clin Pract Oncol. 2007;4(11):643–56.spa
dc.relation.referencesMinisterio de salud y protección [Internet]. Comisión Nacional de Precios de Medicamentos y Dispositivos Médicos. [Internet]. Bogotá: Listado de medicamentos con precio de referencia, [actualizado agosto de 2018]. 2018. Available from: https://www.minsalud.gov.co/salud/MT/Paginas/listado-de-medicamentos-con-precio-controlado.aspxspa
dc.relation.referencesMinisterio de salud y protección [Internet]. Comisión Nacional de Precios de Medicamentos y Dispositivos Médicos. 2018spa
dc.relation.referencesHussain SA, Williams S, Stevens A, Rea DW. Endocrine therapy for early breast cancer. Expert Rev Anticancer Ther. 2004;4(5):877–88.spa
dc.relation.referencesJohnston SJ, Cheung K-L. Endocrine Therapy for Breast Cancer: A Model of Hormonal Manipulation. Oncol Ther [Internet]. 2018;6(2):141–56. Available from: https://doi.org/10.1007/s40487-018-0062-xspa
dc.relation.referencesPruthi S, Heisey RE, Bevers TB. Chemoprevention for Breast Cancer. Ann Surg Oncol. 2015;22(10):3230–5spa
dc.relation.referencesSalkeni M, Hall S. Metastatic breast cancer: Endocrine therapy landscape reshaped. Avicenna J Med. 2017;7(4):144.spa
dc.relation.referencesGoel S, Sharma R, Hamilton A, Beith J. LHRH agonists for adjuvant therapy of early breast cancer in premenopausal women. Cochrane Database Syst Rev. 2009;(4)spa
dc.relation.referencesHeeke A, Nunes MR, Lynce F. Bone-Modifying Agents in Early-Stage and Advanced Breast Cancer. Curr Breast Cancer Rep. 2018;10(4):241–50.spa
dc.relation.referencesRiancho JA, Delgado-Calle J. Mecanismos de interacción osteoblasto-osteoclasto. Reumatol Clin. 2011;7(SUPPL.2):1–4.spa
dc.relation.referencesÁngel J, Mejía A, Guzmán L, Quevedo J, Sánchez R, García O, et al. Mortalidad y recaída en pacientes con cáncer de mama infiltrante sometidas a cirugía conservadora. Rev Colomb Cancerol [Internet]. 2015;19(1):18–28. Available from: http://dx.doi.org/10.1016/j.rccan.2014.09.002spa
dc.relation.referencesMatsen CB, Neumayer LA. Breast cancer: A review for the general surgeon. JAMA Surg. 2013;148(10):971–9.spa
dc.relation.referencesCorrea J. FJ. CR. MJ. CM. SA, F JD, C R, M J, C M. Principios de cirugía oncológica. Rev Colomb Cirugía. 2016;31(3):185–96.spa
dc.relation.referencesPiñeiro G, Perelman S, Guerschman JP, Paruelo JM. How to evaluate models: Observed vs. predicted or predicted vs. observed? Ecol Modell. 2008;216(3–4):316–22.spa
dc.relation.referencesFrançois C. Deep Learning with Python. Manning Publications Co. Shelter Island, NY 11964: Manning Publications Co.; 2018. 56–92 p.spa
dc.relation.referencesTherneau T, Atkinson B, Ripley B. rpart: Recursive partitioning for classification, regression and survival trees. R package version 4.1-15. 2019; Available from: https://cran.r-project.org/package=rpartspa
dc.relation.referencesMilborrow AS. Package ‘rpart.plot.’ 2019;spa
dc.relation.referencesAugustovski F, García Martí S, Pichon-Riviere A. Estándares Consolidados de Reporte de Evaluaciones Económicas Sanitarias: Versión en Español de la Lista de Comprobación CHEERS. Value Heal Reg Issues [Internet]. 2013;2(3):338–41. Available from: http://dx.doi.org/10.1016/j.vhri.2013.10.004spa
dc.rights.accessrightsinfo:eu-repo/semantics/openAccessspa
dc.rights.licenseAtribución-NoComercial-CompartirIgual 4.0 Internacionalspa
dc.rights.urihttp://creativecommons.org/licenses/by-nc-sa/4.0/spa
dc.subject.ddc610 - Medicina y salud::616 - Enfermedadesspa
dc.subject.ddc330 - Economía::336 - Finanzas públicasspa
dc.subject.ddc610 - Medicina y salud::615 - Farmacología y terapéuticaspa
dc.subject.decsCostos de la Atención en Saludspa
dc.subject.decsHealth Care Costseng
dc.subject.decsNeoplasias de la Mamaspa
dc.subject.decsBreast Neoplasmseng
dc.subject.decsModelos Organizacionalesspa
dc.subject.decsModels, Organizationaleng
dc.subject.decsOrganizaciones del Seguro de Saludspa
dc.subject.decsPreferred Provider Organizationseng
dc.subject.proposalEconomía de la salud y organizacionesspa
dc.subject.proposalCostos y análisis de costosspa
dc.subject.proposalCostos de atención médicaspa
dc.subject.proposalCostos directos del serviciospa
dc.subject.proposalNeoplasiasspa
dc.subject.proposalNeoplasias por sitiospa
dc.subject.proposalNeoplasias de la mamaspa
dc.subject.proposalHealth economics and organizationseng
dc.subject.proposalCosts and cost analysiseng
dc.subject.proposalHealth care costseng
dc.subject.proposalDirect service costseng
dc.subject.proposalBreast neoplasmseng
dc.subject.proposalNeoplasmseng
dc.subject.proposalNeoplasms per siteeng
dc.titleEstimación de los costos directos médicos netos de la atención de Cáncer de Mama en el sistema general de seguridad social en salud de Colombiaspa
dc.title.translatedEstimation of the direct net medical costs of breast cancer care in the general social health security system of Colombiaeng
dc.typeTrabajo de grado - Doctoradospa
dc.type.coarhttp://purl.org/coar/resource_type/c_db06spa
dc.type.coarversionhttp://purl.org/coar/version/c_ab4af688f83e57aaspa
dc.type.contentDataPaperspa
dc.type.contentTextspa
dc.type.driverinfo:eu-repo/semantics/doctoralThesisspa
dc.type.redcolhttp://purl.org/redcol/resource_type/TDspa
dc.type.versioninfo:eu-repo/semantics/acceptedVersionspa
dcterms.audience.professionaldevelopmentInvestigadoresspa
oaire.accessrightshttp://purl.org/coar/access_right/c_abf2spa

Archivos

Bloque original

Mostrando 1 - 1 de 1
Miniatura
Nombre:
79056498.2020.pdf
Tamaño:
3.1 MB
Formato:
Adobe Portable Document Format
Descripción:
Tesis de Doctorado en Ciencias Farmacéuticas
Descargar

Bloque de licencias

Mostrando 1 - 1 de 1
Miniatura
Nombre:
license.txt
Tamaño:
5.74 KB
Formato:
Item-specific license agreed upon to submission
Descripción:
Descargar

Colecciones

Doctorado en Ciencias Farmacéuticas